1
|
Rox K, Jansen R, Loof TG, Gillen CM, Bernecker S, Walker MJ, Chhatwal GS, Müller R. Linoleic and palmitoleic acid block streptokinase-mediated plasminogen activation and reduce severity of invasive group A streptococcal infection. Sci Rep 2017; 7:11798. [PMID: 28924140 PMCID: PMC5603603 DOI: 10.1038/s41598-017-11276-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Accepted: 08/17/2017] [Indexed: 01/06/2023] Open
Abstract
In contrast to mild infections of Group A Streptococcus (GAS) invasive infections of GAS still pose a serious health hazard: GAS disseminates from sterile sites into the blood stream or deep tissues and causes sepsis or necrotizing fasciitis. In this case antibiotics do not provide an effective cure as the bacteria are capable to hide from them very quickly. Therefore, new remedies are urgently needed. Starting from a myxobacterial natural products screening campaign, we identified two fatty acids isolated from myxobacteria, linoleic and palmitoleic acid, specifically blocking streptokinase-mediated activation of plasminogen and thereby preventing streptococci from hijacking the host’s plasminogen/plasmin system. This activity is not inherited by other fatty acids such as oleic acid and is not attributable to the killing of streptococci. Moreover, both fatty acids are superior in their inhibitory properties compared to two clinically used drugs (tranexamic or ε-amino caproic acid) as they show 500–1000 fold lower IC50 values. Using a humanized plasminogen mouse model mimicking the clinical situation of a local GAS infection that becomes systemic, we demonstrate that these fatty acids ameliorate invasive GAS infection significantly. Consequently, linoleic and palmitoleic acid are possible new options to combat GAS invasive diseases.
Collapse
Affiliation(s)
- Katharina Rox
- Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University, Saarbrücken, Germany.,Department of Medical Microbiology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.,Central facility for Microscopy, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.,German Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover, Hannover, Germany
| | - Rolf Jansen
- Department of Microbial Drugs, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.,German Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover, Hannover, Germany
| | - Torsten G Loof
- Department of Medical Microbiology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.,Infection Immunology Research Group, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany
| | - Christine M Gillen
- School of Chemistry and Molecular Biosciences and Australian Infectious Disease Research Centre, The University of Queensland, St. Lucia, Queensland, Australia
| | - Steffen Bernecker
- Department of Microbial Drugs, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.,German Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover, Hannover, Germany
| | - Mark J Walker
- School of Chemistry and Molecular Biosciences and Australian Infectious Disease Research Centre, The University of Queensland, St. Lucia, Queensland, Australia
| | - Gursharan Singh Chhatwal
- Department of Medical Microbiology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany
| | - Rolf Müller
- Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University, Saarbrücken, Germany. .,German Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover, Hannover, Germany.
| |
Collapse
|
2
|
Huish S, Thelwell C, Longstaff C. Activity Regulation by Fibrinogen and Fibrin of Streptokinase from Streptococcus Pyogenes. PLoS One 2017; 12:e0170936. [PMID: 28125743 PMCID: PMC5268773 DOI: 10.1371/journal.pone.0170936] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Accepted: 01/12/2017] [Indexed: 01/26/2023] Open
Abstract
Streptokinase is a virulence factor of streptococci and acts as a plasminogen activator to generate the serine protease plasmin which promotes bacterial metastasis. Streptokinase isolated from group C streptococci has been used therapeutically as a thrombolytic agent for many years and its mechanism of action has been extensively studied. However, group A streptococci are associated with invasive and potentially fatal infections, but less detail is available on the mechanism of action of streptokinase from these bacteria. We have expressed recombinant streptokinase from a group C strain to investigate the therapeutic molecule (here termed rSK-H46A) and a molecule isolated from a cluster 2a strain from group A (rSK-M1GAS) which is known to produce the fibrinogen binding, M1 protein, and is associated with life-threatening disease. Detailed enzyme kinetic models have been prepared which show how fibrinogen-streptokinase-plasminogen complexes regulate plasmin generation, and also the effect of fibrin interactions. As is the case with rSK-H46A our data with rSK-M1GAS support a "trigger and bullet" mechanism requiring the initial formation of SK•plasminogen complexes which are replaced by more active SK•plasmin as plasmin becomes available. This model includes the important fibrinogen interactions that stimulate plasmin generation. In a fibrin matrix rSK-M1GAS has a 24 fold higher specific activity than the fibrin-specific thrombolytic agent, tissue plasminogen activator, and 15 fold higher specific activity than rSK-H46A. However, in vivo fibrin specificity would be undermined by fibrinogen stimulation. Given the observed importance of M1 surface receptors or released M1 protein to virulence of cluster 2a strain streptococci, studies on streptokinase activity regulation by fibrin and fibrinogen may provide additional routes to addressing bacterial invasion and infectious diseases.
Collapse
Affiliation(s)
- Sian Huish
- Component development laboratory, NHS Blood and Transplant, Cambridge Donor Centre, Cambridge, United Kingdom
| | - Craig Thelwell
- Biotherapeutics Section, National Institute for Biological Standard and Control, South Mimms, Herts, United Kingdom
| | - Colin Longstaff
- Biotherapeutics Section, National Institute for Biological Standard and Control, South Mimms, Herts, United Kingdom
- * E-mail:
| |
Collapse
|
3
|
Abstract
Group A streptococci (GAS) express soluble and surface-bound virulence factors. Secreted streptokinase (SK) allelic variants exhibit varying abilities to activate host plasminogen (Pg), and GAS pathogenicity is associated with Pg activation and localization of the resulting plasmin (Pm) on the bacterial surface to promote dissemination. The various mechanisms by which GAS usurp the host proteolytic system are discussed, including the molecular sexuality mechanism of conformational activation of the Pg zymogen (Pg*) and subsequent proteolytic activation of substrate Pg by the S•KPg* and SK•Pm catalytic complexes. Substantial progress has been made to delineate both processes in a unified mechanism. Pm coats the bacteria by direct and indirect binding pathways involving plasminogen-binding group A streptococcal M-like (PAM) protein and host fibrin(ogen). Transgenic mouse models using human Pg are being optimized to mimic infections by SK variants in humans and to define in vivo combined mechanisms of these variants and PAM.
Collapse
Affiliation(s)
- I M Verhamme
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - P R Panizzi
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA
| | - P E Bock
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA
| |
Collapse
|
4
|
Xu Y, Yu H, Sun H. Targeting the host hemostatic system function in bacterial infection for antimicrobial therapies. J Thromb Thrombolysis 2014; 37:66-73. [PMID: 24379143 DOI: 10.1007/s11239-013-0994-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The hemostatic system is an important player in host's response to infection. It has been shown that host hemostatic factors as well as platelets, interact with various proteins from bacteria and play important roles in host defense against infections. This review summarizes studies of function of host hemostatic system in host defense against bacterial infections and efforts to target hemostatic system interaction with pathogens to develop potential antimicrobial therapies.
Collapse
Affiliation(s)
- Yuanxi Xu
- Department of Internal Medicine, University of Missouri Hospital and Clinics, Columbia, MO, USA
| | | | | |
Collapse
|
5
|
Oehmcke S, Westman J, Malmström J, Mörgelin M, Olin AI, Kreikemeyer B, Herwald H. A novel role for pro-coagulant microvesicles in the early host defense against streptococcus pyogenes. PLoS Pathog 2013; 9:e1003529. [PMID: 23935504 PMCID: PMC3731245 DOI: 10.1371/journal.ppat.1003529] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2013] [Accepted: 06/15/2013] [Indexed: 01/30/2023] Open
Abstract
Previous studies have shown that stimulation of whole blood or peripheral blood mononuclear cells with bacterial virulence factors results in the sequestration of pro-coagulant microvesicles (MVs). These particles explore their clotting activity via the extrinsic and intrinsic pathway of coagulation; however, their pathophysiological role in infectious diseases remains enigmatic. Here we describe that the interaction of pro-coagulant MVs with bacteria of the species Streptococcus pyogenes is part of the early immune response to the invading pathogen. As shown by negative staining electron microscopy and clotting assays, pro-coagulant MVs bind in the presence of plasma to the bacterial surface. Fibrinogen was identified as a linker that, through binding to the M1 protein of S. pyogenes, allows the opsonization of the bacteria by MVs. Surface plasmon resonance analysis revealed a strong interaction between pro-coagulant MVs and fibrinogen with a KD value in the nanomolar range. When performing a mass-spectrometry-based strategy to determine the protein quantity, a significant up-regulation of the fibrinogen-binding integrins CD18 and CD11b on pro-coagulant MVs was recorded. Finally we show that plasma clots induced by pro-coagulant MVs are able to prevent bacterial dissemination and possess antimicrobial activity. These findings were confirmed by in vivo experiments, as local treatment with pro-coagulant MVs dampens bacterial spreading to other organs and improved survival in an invasive streptococcal mouse model of infection. Taken together, our data implicate that pro-coagulant MVs play an important role in the early response of the innate immune system in infectious diseases. The coagulation system is much more than a passive bystander in our defense against exogenous microorganisms. Over the last years there has been a growing body of evidence pointing to an integral part of coagulation in innate immunity and a special focus has been on bacterial entrapment in a fibrin network. However, thus far, pro-coagulant MVs have not been discussed in this context, though it is known that their numbers can dramatically increase in many pathological conditions, including severe infectious diseases. In the present study we see a significant increase of pro-coagulant MVs in an invasive streptococcal mouse model, suggesting that their release is an immune response to the infection. We find that pro-coagulant MVs bind to Streptococcus pyogenes and promote clotting, entrapment, and killing of the bacteria in a fibrin network. As a proof of concept pro-coagulant MVs were applied as local treatment in the streptococcal infection model, and it was demonstrated that this led to a significantly improved survival in mice.
Collapse
Affiliation(s)
- Sonja Oehmcke
- University Medicine, Institute of Medical Microbiology, Virology and Hygiene, Rostock University, Rostock, Germany.
| | | | | | | | | | | | | |
Collapse
|
6
|
Sanderson-Smith ML, Zhang Y, Ly D, Donahue D, Hollands A, Nizet V, Ranson M, Ploplis VA, Walker MJ, Castellino FJ. A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection. PLoS Pathog 2013; 9:e1003469. [PMID: 23853591 PMCID: PMC3701706 DOI: 10.1371/journal.ppat.1003469] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Accepted: 05/15/2013] [Indexed: 12/03/2022] Open
Abstract
Recruitment of the serine protease plasmin is central to the pathogenesis of many bacterial species, including Group A streptococcus (GAS), a leading cause of morbidity and mortality globally. A key process in invasive GAS disease is the ability to accumulate plasmin at the cell surface, however the role of host activators of plasminogen in this process is poorly understood. Here, we demonstrate for the first time that the urokinase-type plasminogen activator (uPA) contributes to plasmin recruitment and subsequent invasive disease initiation in vivo. In the absence of a source of host plasminogen activators, streptokinase (Ska) was required to facilitate cell surface plasmin acquisition by GAS. However, in the absence of Ska, host activators were sufficient to promote cell surface plasmin acquisition by GAS strain 5448 during incubation with plasminogen or human plasma. Furthermore, GAS were able mediate a significant increase in the activation of zymogen pro-uPA in human plasma. In order to assess the contribution of uPA to invasive GAS disease, a previously undescribed transgenic mouse model of infection was employed. Both C57/black 6J, and AlbPLG1 mice expressing the human plasminogen transgene, were significantly more susceptible to invasive GAS disease than uPA−/− mice. The observed decrease in virulence in uPA−/−mice was found to correlate directly with a decrease in bacterial dissemination and reduced cell surface plasmin accumulation by GAS. These findings have significant implications for our understanding of GAS pathogenesis, and research aimed at therapeutic targeting of plasminogen activation in invasive bacterial infections. Subversion of the host fibrinolytic system by bacterial pathogens is recognised as a key process in severe disease initiation. Co-opting of plasmin by bacteria contributes to tissue destruction and bacterial dissemination, both hallmarks of invasive Group A streptococcal disease, and research aimed at therapeutic targeting of the nexus between group A streptococcus and the fibrinolytic system is increasing. The host plasminogen activator uPA is found at the surface of cells that contribute to epithelial and innate immune defense against bacterial infection, and may contribute to bacterial recruitment of plasmin, however, the role of uPA in group A streptococcal infection is not well characterised. Here, we describe for the first time the key role played by uPA in invasive group A streptococcal disease. The ability of this pathogen to cause severe infection, even in the absence of the bacterial plasminogen activator streptokinase, has significant implications for the development of therapeutics to control invasive bacterial infection.
Collapse
Affiliation(s)
- Martina L Sanderson-Smith
- Ilawarra Health and Medical Research Institute and School of Biological Sciences, University of Wollongong, Wollongong, New South Wales, Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Ma Y, Xu Y, Yestrepsky BD, Sorenson RJ, Chen M, Larsen SD, Sun H. Novel inhibitors of Staphylococcus aureus virulence gene expression and biofilm formation. PLoS One 2012; 7:e47255. [PMID: 23077578 PMCID: PMC3471953 DOI: 10.1371/journal.pone.0047255] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2012] [Accepted: 09/10/2012] [Indexed: 12/27/2022] Open
Abstract
Staphylococcus aureus is a major human pathogen and one of the more prominent pathogens causing biofilm related infections in clinic. Antibiotic resistance in S. aureus such as methicillin resistance is approaching an epidemic level. Antibiotic resistance is widespread among major human pathogens and poses a serious problem for public health. Conventional antibiotics are either bacteriostatic or bacteriocidal, leading to strong selection for antibiotic resistant pathogens. An alternative approach of inhibiting pathogen virulence without inhibiting bacterial growth may minimize the selection pressure for resistance. In previous studies, we identified a chemical series of low molecular weight compounds capable of inhibiting group A streptococcus virulence following this alternative anti-microbial approach. In the current study, we demonstrated that two analogs of this class of novel anti-virulence compounds also inhibited virulence gene expression of S. aureus and exhibited an inhibitory effect on S. aureus biofilm formation. This class of anti-virulence compounds could be a starting point for development of novel anti-microbial agents against S. aureus.
Collapse
Affiliation(s)
- Yibao Ma
- Department of Internal Medicine, University of Missouri, Columbia, Missouri, United States of America
| | - Yuanxi Xu
- Department of Internal Medicine, University of Missouri, Columbia, Missouri, United States of America
| | - Bryan D. Yestrepsky
- Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Roderick J. Sorenson
- Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Meng Chen
- Nanova, Inc., Columbia, Missouri, United States of America
| | - Scott D. Larsen
- Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, United States of America
- * E-mail: (HS); (SDL)
| | - Hongmin Sun
- Department of Internal Medicine, University of Missouri, Columbia, Missouri, United States of America
- * E-mail: (HS); (SDL)
| |
Collapse
|
8
|
Deeks ED. Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery. Drugs 2012; 72:1271-91. [PMID: 22686618 DOI: 10.2165/11209020-000000000-00000] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Apixaban (Eliquis™) is an orally active and selective direct inhibitor of factor Xa indicated for twice-daily use in the EU for the prevention of venous thromboembolism (VTE) in adults who have had knee or hip replacement surgery. In this article, the pharmacological, clinical efficacy and tolerability data relevant to the use of apixaban in this indication are reviewed. Oral apixaban is a generally effective and well tolerated thromboprophylactic agent for use after major orthopaedic surgery. In the large, randomized, double-blind, phase III, noninferiority trials known as ADVANCE-2 and -3, apixaban 2.5 mg twice daily initiated after surgery was generally more effective in preventing VTE in patients undergoing knee or hip replacement surgery than subcutaneous enoxaparin sodium initiated before surgery at the EU recommended dosage of 40 mg once daily, with apixaban conferring this benefit without significantly increasing the risk of bleeding. However, when the same apixaban regimen was compared with the US recommended dosage regimen of subcutaneous enoxaparin sodium (30 mg twice daily, initiated after surgery) in patients undergoing knee replacement surgery in the similarly designed ADVANCE-1 trial, the thromboprophylactic efficacy of apixaban did not meet primary endpoint noninferiority criteria, although apixaban was associated with fewer major or clinically relevant nonmajor bleeds (composite endpoint) than this enoxaparin sodium regimen. Additional comparative efficacy and tolerability data are required to definitively position apixaban with respect to other anticoagulants, including rivaroxaban and dabigatran etexilate. In the meantime, currently available clinical data indicate that apixaban is an emerging option for the prevention of VTE in patients undergoing knee or hip replacement surgery.
Collapse
|